查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571951

液態切片的全球市場

Breast Cancer Liquid Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2030年全球液態切片市場將達到11億美元

2023年全球液態切片市場估計為2.779億美元，預計到2030年將達到11億美元，2023-2030年分析期間複合年成長率為21.4%。試劑組是本報告分析的細分市場之一，預計複合年成長率為 22.0%，到分析期結束時將達到 8.193 億美元。分析期間內，設備領域的複合年成長率預計為 21.0%。

美國市場預計7,700萬美元，中國預期複合年成長率20.4%

預計 2023 年美國液態切片市場規模將達到 7,700 萬美元。中國作為全球第二大經濟體，預計2030年市場規模將達到1.614億美元，2023-2030年分析期間複合年成長率為20.4%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 19.0% 和 18.4%。在歐洲，德國的複合年成長率預計約為 15.8%。

全球液態切片市場 - 主要趨勢和促進因素總結

液態切片將如何徹底改變乳癌的診斷和治療？

液態切片提供了一種微創方法，透過分析循環性腫瘤細胞(CTC)、循環腫瘤DNA (ctDNA) 以及血液和其他體液中存在的其他生物標記來檢測和監測癌症。正在徹底改變診斷方法。傳統上，乳癌的診斷在很大程度上依賴組織切片檢查，即透過手術切除腫瘤樣本並進行分析。液態切片提供了一種侵入性較小的替代方案，可以頻繁監測和早期檢測基因突變、抗治療性和腫瘤進展，而無需手術。這對於因健康狀況或腫瘤位置而無法重複侵入性手術的患者尤其有益。

液態切片技術的關鍵進步之一是它能夠即時了解癌症的分子特徵並實現個人化治療策略。透過分析ctDNA和CTC，腫瘤學家可以識別驅動癌症進展的特定基因突變，例如HER2和BRCA突變，這可以指南標靶治療的選擇。此外，液態切片可以持續監測治療效果，使醫生能夠及早發現抗藥性並相應調整治療計劃。這種精準醫療方法正在為患者提供更個人化、有效且適應性強的治療選擇，從而改變乳癌的治療方法。

液態切片在乳癌的早期檢測和監測中發揮什麼作用？

液態切片在乳癌的早期檢測和監測中發揮著重要作用，它使臨床醫生能夠在透過影像或身體檢查檢測到癌症突變和腫瘤動態變化之前識別它們。早期乳癌通常無症狀，傳統的診斷方法（例如乳房X光檢查和組織切片檢查）可能會漏掉小或早期的病灶。然而，液態切片可以檢測到腫瘤排放到血流中的微量 ctDNA，從而提供了一種早期檢測癌症的非侵入性方法。早期檢測可以增加治療成功的可能性並降低轉移風險，這對於改善患者預後至關重要。

除了早期檢測之外，液態切片還可用於在乳癌患者的整個病人歷程過程中進行持續監測。透過追蹤 ctDNA 或 CTC 水平的變化，臨床醫生可以評估患者對治療的反應情況，檢測微量殘存疾病(MRD)，並透過傳統影像方式檢測明顯的腫瘤生長，您可以在復發跡象發生之前識別。這種即時監測癌症進展的能力可以實現更動態和個人化的治療計劃，提高整體存活率並減少對更具侵入性檢測的需求。隨著液態切片技術的不斷發展，預計它將成為乳癌早期檢測和長期患者監測的標準工具。

液態切片如何推進乳癌的個人化醫療？

液態切片能夠更深入了解每位患者腫瘤的遺傳和分子狀況，處於推動乳癌個人化醫療的最前線。透過ctDNA分析，液態切片可以識別特定的基因突變，例如PIK3CA、ESR1和BRCA1/2。這些資訊使腫瘤學家能夠根據每位患者獨特的癌症特徵量身定做治療方案，並根據可操作突變的存在選擇最有效的治療方法。例如，HER2 陽性乳癌患者可能受益於曲妥珠單抗等標靶治療，而 BRCA 突變患者可能對 PARP 抑制劑有更好的反應。

液態切片還可以幫助識別抗治療性的出現，這是乳癌治療的通用挑戰。隨著時間的推移，癌細胞可以獲得新的突變，幫助它們逃避化療和標靶治療的作用。液態切片使臨床醫生能夠及早發現這些抗藥性突變，從而有可能使他們能夠在癌症進一步進展之前調整治療策略或轉向替代療法。透過提供對腫瘤進展的即時分子洞察，液態切片正在為個人化醫療方法提供動力，以最佳化乳癌患者的治療效果並最大程度地減少不必要的副作用。

推動液態切片市場成長的因素有哪些？

液態切片市場的成長是由幾個關鍵因素推動的，例如對非侵入性診斷方法的需求不斷增加、精準醫學的進步以及全球乳癌發病率的上升。液態切片提供了一種比組織切片檢查更安全、侵入性更小的替代方法，因此患者選擇這種方法，特別是對於需要頻繁監測或不適合傳統切片檢查和醫療保健提供者的患者。在治療期間進行重複液態切片的能力還可以持續監測疾病進展，有助於改善患者的治療結果。

液態切片平台的技術進步，例如次世代定序(NGS) 和數位 PCR，正在提高這些測試的靈敏度和準確性，進一步推動市場採用。對個人化醫療和標靶治療的日益關注也是推動市場成長的關鍵因素，因為液態切片提供了為個別患者量身定做治療所需的分子見解。此外，全球乳癌發生率的增加增加了對早期檢測和監測工具的需求，從而促進了液態切片市場的擴大。隨著醫療保健系統越來越重視精準腫瘤學和非侵入性診斷，液態切片市場預計將在未來幾年持續成長。

受訪企業範例（34家知名企業）

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science BV
  • Menarini Silicon Biosystems
  • Myriad Genetics

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP21384

Global Breast Cancer Liquid Biopsy Market to Reach US$1.1 Billion by 2030

The global market for Breast Cancer Liquid Biopsy estimated at US$277.9 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 21.4% over the analysis period 2023-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.0% CAGR and reach US$819.3 Million by the end of the analysis period. Growth in the Instruments segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$77.0 Million While China is Forecast to Grow at 20.4% CAGR

The Breast Cancer Liquid Biopsy market in the U.S. is estimated at US$77.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$161.4 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.0% and 18.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.8% CAGR.

Global Breast Cancer Liquid Biopsy Market – Key Trends & Drivers Summarized

How Are Liquid Biopsies Transforming Breast Cancer Diagnosis and Treatment?

Liquid biopsies are revolutionizing breast cancer diagnosis and treatment by providing a minimally invasive method for detecting and monitoring cancer through the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other biomarkers present in blood or other bodily fluids. Traditionally, breast cancer diagnosis relied heavily on tissue biopsies, which involve surgically removing a sample of the tumor for analysis. Liquid biopsies offer a less invasive alternative, allowing for frequent monitoring and early detection of genetic mutations, treatment resistance, and tumor progression without the need for surgery. This is particularly beneficial for patients who cannot undergo repeated invasive procedures due to health conditions or the location of the tumor.

One of the key advancements in liquid biopsy technology is its ability to provide real-time insights into the molecular profile of the cancer, enabling personalized treatment strategies. By analyzing ctDNA and CTCs, oncologists can identify specific genetic mutations driving the cancer, such as HER2 or BRCA mutations, which can guide the selection of targeted therapies. Moreover, liquid biopsies allow for the continuous monitoring of treatment effectiveness, helping doctors detect drug resistance early and adjust treatment plans accordingly. This precision medicine approach is transforming breast cancer care by offering more personalized, effective, and adaptive treatment options for patients.

What Role Do Liquid Biopsies Play in Early Detection and Monitoring of Breast Cancer?

Liquid biopsies play a crucial role in the early detection and monitoring of breast cancer by allowing clinicians to identify cancerous mutations and changes in tumor dynamics before they become detectable through imaging or physical examination. Early-stage breast cancer is often asymptomatic, and traditional diagnostic methods such as mammograms or tissue biopsies may miss small or early lesions. Liquid biopsies, however, can detect minute amounts of ctDNA shed by tumors into the bloodstream, providing a non-invasive method to identify cancer at an earlier stage. Early detection is critical for improving patient outcomes, as it increases the chances of successful treatment and reduces the risk of metastasis.

In addition to early detection, liquid biopsies are valuable for ongoing monitoring of breast cancer patients throughout their treatment journey. By tracking changes in ctDNA or CTC levels, clinicians can assess how well a patient is responding to therapy, detect minimal residual disease (MRD), and identify signs of relapse before traditional imaging methods reveal tumor growth. This ability to monitor cancer progression in real time allows for more dynamic and personalized treatment plans, improving overall survival rates and reducing the need for more invasive tests. As liquid biopsy technology continues to evolve, it is expected to become a standard tool in both early breast cancer detection and long-term patient monitoring.

How Are Liquid Biopsies Advancing Personalized Medicine in Breast Cancer?

Liquid biopsies are at the forefront of advancing personalized medicine in breast cancer by enabling a deeper understanding of the genetic and molecular landscape of each patient’s tumor. Through the analysis of ctDNA, liquid biopsies can identify specific genetic mutations, such as PIK3CA, ESR1, or BRCA1/2, which may influence how a patient responds to certain therapies. This information allows oncologists to tailor treatments to the individual patient’s unique cancer profile, selecting therapies that are most likely to be effective based on the presence of actionable mutations. For example, patients with HER2-positive breast cancer may benefit from targeted therapies like trastuzumab, while those with BRCA mutations may respond better to PARP inhibitors.

Liquid biopsies also help in identifying the emergence of treatment resistance, a common challenge in breast cancer management. Over time, cancer cells can acquire new mutations that allow them to evade the effects of chemotherapy or targeted therapies. Liquid biopsies enable clinicians to detect these resistance mutations early, allowing them to adjust treatment strategies and potentially switch to alternative therapies before the cancer progresses further. By providing real-time, molecular-level insights into the tumor’s evolution, liquid biopsies are empowering personalized medicine approaches that optimize treatment efficacy and minimize unnecessary side effects for breast cancer patients.

What Factors Are Driving the Growth of the Breast Cancer Liquid Biopsy Market?

The growth of the breast cancer liquid biopsy market is driven by several key factors, including the increasing demand for non-invasive diagnostic methods, advancements in precision medicine, and the rising incidence of breast cancer globally. As liquid biopsies offer a safer, less invasive alternative to tissue biopsies, more patients and healthcare providers are opting for this approach, particularly for patients who require frequent monitoring or those who are not candidates for traditional biopsies. The ability to perform repeated liquid biopsies over the course of treatment also allows for continuous monitoring of disease progression, helping to improve patient outcomes.

Technological advancements in liquid biopsy platforms, such as next-generation sequencing (NGS) and digital PCR, are enhancing the sensitivity and accuracy of these tests, further driving market adoption. The growing focus on personalized medicine and targeted therapies is another major factor fueling market growth, as liquid biopsies provide the molecular insights needed to tailor treatments to individual patients. Additionally, the increasing prevalence of breast cancer worldwide is creating a higher demand for early detection and monitoring tools, contributing to the expansion of the liquid biopsy market. As healthcare systems increasingly prioritize precision oncology and non-invasive diagnostics, the breast cancer liquid biopsy market is expected to experience sustained growth in the coming years.

Select Competitors (Total 34 Featured) -

  • Biodesix, Inc.
  • Bio-Rad Laboratories
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina
  • Isogen Life Science B.V.
  • Menarini Silicon Biosystems
  • Myriad Genetics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Breast Cancer Liquid Biopsy - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Breast Cancer Globally Drives Growth in the Breast Cancer Liquid Biopsy Market
    • Increasing Demand for Non-Invasive Diagnostics Expands the Addressable Market for Liquid Biopsies in Breast Cancer
    • Technological Advancements in Circulating Tumor DNA (ctDNA) and Cell-Free DNA (cfDNA) Testing Propel Innovation in Breast Cancer Liquid Biopsy
    • Growing Focus on Early Detection and Monitoring of Breast Cancer Strengthens the Business Case for Liquid Biopsy Solutions
    • Rising Adoption of Liquid Biopsies in Precision Medicine and Targeted Therapy Selection Fuels Market Growth
    • Increasing Use of Liquid Biopsies in Monitoring Treatment Response and Disease Recurrence Expands Applications in Breast Cancer Care
    • Technological Innovations in Next-Generation Sequencing (NGS) Propel Growth in High-Sensitivity Liquid Biopsy Platforms
    • Growing Focus on Minimally Invasive Cancer Diagnostics Expands the Market for Breast Cancer Liquid Biopsy
    • Rising Investment in Biomarker Discovery and Validation Strengthens Market Growth for Breast Cancer Liquid Biopsies
    • Growing Use of Liquid Biopsy for Companion Diagnostics in Breast Cancer Therapies Expands Market Reach
    • Technological Advancements in Exosome-Based and Protein Biomarker Detection Propel Growth in Breast Cancer Liquid Biopsies
    • Rising Focus on Liquid Biopsy for Real-Time Cancer Monitoring and Personalized Treatment Drives Adoption in Oncology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Breast Cancer Liquid Biopsy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Risk Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Risk Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Reagent Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Reagent Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Circulating Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Circulating Tumor DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • JAPAN
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • CHINA
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • EUROPE
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Breast Cancer Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • FRANCE
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • GERMANY
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Breast Cancer Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Product & Service - Reagent Kits, Instruments and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Product & Service - Percentage Breakdown of Value Sales for Reagent Kits, Instruments and Services for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Application - Diagnostics, Prognostics and Risk Assessment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Diagnostics, Prognostics and Risk Assessment for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Breast Cancer Liquid Biopsy by Circulating Biomarker - Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Breast Cancer Liquid Biopsy by Circulating Biomarker - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Extracellular Vesicles and Circulating Tumor DNA for the Years 2014, 2024 & 2030

IV. COMPETITION